Integrated multi-omics and experimental analyses identify three post-translational modification genes driving osteosarcoma progression and prognosis

Osteosarcoma is a dangerous form of bone cancer that strikes most often in teenagers and young adults. It is an aggressive disease that spreads quickly to other parts of the body, making it difficult to treat and often leading to poor outcomes for patients. While doctors currently rely on surgery and strong chemotherapy drugs, these treatments do not always work, especially when the cancer returns or has already spread. To find better ways to help, scientists are looking deeper into the biology of the tumor, searching for the specific molecular switches that turn healthy cells into cancerous ones. One area of intense focus is a process called post-translational modification. You can think of this as a set of chemical tags that cells attach to proteins after they are built. These tags do not change the protein's blueprint, but they act like volume knobs or on-off switches, altering how the protein behaves, how long it lasts, and where it goes inside the cell. When these tagging systems go wrong, they can drive a tumor to grow faster and resist treatment. Understanding which specific genes control these tagging processes in bone cancer could reveal new targets for therapy and better ways to predict how a patient will fare.

A team of researchers from Shanghai Jiao Tong University and the Shanghai Children's Medical Center set out to find these critical genes. They began by gathering a massive amount of genetic data from three different public databases, combining thousands of samples from osteosarcoma patients and healthy individuals. By using powerful computer tools to clean up the data and remove technical differences between the various studies, they created a single, unified picture of the disease. They then filtered this massive list of genes through several layers of biological knowledge, looking specifically for those involved in the chemical tagging process and known to be linked to bone cancer. This rigorous process of elimination narrowed the field down to just three genes: VCAN, RRP12, and CREG1. These three stood out because they showed distinct patterns of activity in tumor tissue compared to normal tissue, and they appeared to work together in a coordinated way to influence the cancer's behavior.

To see if these three genes could actually predict the future of a patient, the researchers built a mathematical model using data from another large group of patients. They assigned a risk score to each person based on how active these three genes were in their tumor. The results were striking. Patients whose tumors showed high activity of the VCAN and CREG1 genes, combined with low activity of the RRP12 gene, had a much higher chance of dying from the disease. The model was able to separate patients into high-risk and low-risk groups with remarkable accuracy, far better than looking at any single gene on its own. This suggests that the combined activity of these three genes serves as a powerful warning signal for doctors, offering a new way to identify which patients might need more aggressive treatment.

The team did not stop at computer analysis; they wanted to prove that these genes were actually doing something harmful inside the cells. They focused on one of the three, CREG1, to test its role directly. Using a technique that acts like a molecular silencer, they turned down the activity of the CREG1 gene in two different types of osteosarcoma cells grown in the lab. The effect was immediate and clear. When the cells could no longer produce normal levels of CREG1, they stopped growing as fast and lost their ability to move and invade surrounding tissue. In experiments where the cells were placed in a dish to see how quickly they could close a gap, the silenced cells moved much slower than the normal ones. This confirmed that CREG1 is not just a bystander but a driver that helps the cancer spread and survive.

Finally, the researchers looked for potential treatments that might target this specific weakness. They used a database that tracks how thousands of different drugs change gene activity in cells. They found that several existing compounds, including a chemotherapy drug called mercaptopurine and two other experimental molecules, showed a strong ability to reverse the genetic signature caused by high levels of CREG1. This suggests that these drugs might be able to counteract the aggressive behavior driven by the gene. Furthermore, the study showed that tumors with high levels of CREG1 tended to be less sensitive to many common cancer drugs, hinting that this gene might be a key reason why some patients do not respond to standard chemotherapy. By combining deep data analysis with hands-on lab experiments, this work has identified a small but powerful set of genes that control the fate of osteosarcoma, offering a new map for understanding the disease and a potential path toward more precise, effective treatments.